LeMaitre Vascular (NASDAQ:LMAT) Shares Gap Down on Disappointing Earnings

LeMaitre Vascular, Inc. (NASDAQ:LMAT)’s share price gapped down before the market opened on Wednesday following a weaker than expected earnings announcement. The stock had previously closed at $105.78, but opened at $88.15. LeMaitre Vascular shares last traded at $88.00, with a volume of 234,198 shares traded.

The medical instruments supplier reported $0.74 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.81 by ($0.07). LeMaitre Vascular had a net margin of 24.35% and a return on equity of 15.36%. The company had revenue of $70.38 million during the quarter, compared to analyst estimates of $71.47 million. During the same period in the previous year, the firm posted $0.60 EPS. The company’s revenue for the quarter was up 9.6% on a year-over-year basis.

LeMaitre Vascular Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Thursday, September 3rd. Stockholders of record on Thursday, August 20th will be paid a $0.25 dividend. This represents a $1.00 annualized dividend and a dividend yield of 1.2%. The ex-dividend date is Thursday, August 20th. LeMaitre Vascular’s dividend payout ratio (DPR) is 36.90%.

Trending Headlines about LeMaitre Vascular

Here are the key news stories impacting LeMaitre Vascular this week:

• Positive Sentiment: LeMaitre reported second-quarter revenue of $70.38 million, up 9.6% year over year, while earnings increased to $0.74 per share from $0.60 a year earlier. The company also declared a quarterly dividend of $0.25 per share, payable September 3 to shareholders of record August 20, implying an annualized yield of approximately 0.9%. LeMaitre Q2 2026 Financial Results
• Neutral Sentiment: The company’s Q4 2026 EPS outlook of $0.75-$0.81 brackets the $0.79 analyst consensus, suggesting near-term results may be broadly in line with expectations. Q2 2026 Earnings Call Transcript
• Negative Sentiment: Second-quarter EPS of $0.74 missed the $0.81 consensus estimate, while revenue of $70.38 million was below expectations of $71.47 million. The earnings miss may weigh on the stock, despite year-over-year growth. LeMaitre Vascular Q2 Earnings and Revenues Lag Estimates
• Negative Sentiment: LeMaitre reduced its third-quarter EPS guidance to $0.66-$0.71 versus the $0.73 consensus and lowered full-year EPS guidance to $2.84-$2.94 versus $3.00 expected. Full-year revenue guidance of $274.3 million-$278.3 million also trails the $279.9 million consensus.
• Negative Sentiment: Barrington Research downgraded LMAT from “outperform” to “market perform,” signaling reduced conviction in further share-price outperformance. Finviz

Analyst Upgrades and Downgrades

A number of brokerages have weighed in on LMAT. Citizens Jmp lifted their price objective on LeMaitre Vascular from $118.00 to $127.00 and gave the company a “market outperform” rating in a report on Wednesday, May 6th. Citigroup reissued a “market outperform” rating on shares of LeMaitre Vascular in a report on Tuesday, July 21st. Wells Fargo & Company upped their price objective on LeMaitre Vascular from $94.00 to $104.00 and gave the stock an “equal weight” rating in a report on Wednesday, May 6th. Barrington Research cut shares of LeMaitre Vascular from an “outperform” rating to a “market perform” rating in a research note on Wednesday. Finally, Weiss Ratings cut shares of LeMaitre Vascular from a “buy (b)” rating to a “buy (b-)” rating in a research note on Tuesday, June 30th. Four equities research analysts have rated the stock with a Buy rating and five have issued a Hold rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Hold” and an average target price of $112.60.

Insider Buying and Selling

In other LeMaitre Vascular news, CEO George W. Lemaitre sold 27,881 shares of the company’s stock in a transaction on Friday, May 8th. The stock was sold at an average price of $108.69, for a total value of $3,030,385.89. Following the sale, the chief executive officer owned 1,430,019 shares of the company’s stock, valued at approximately $155,428,765.11. This represents a 1.91% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Trent G. Kamke sold 2,928 shares of the business’s stock in a transaction dated Friday, May 8th. The stock was sold at an average price of $107.00, for a total transaction of $313,296.00. Following the completion of the sale, the insider owned 3,749 shares in the company, valued at $401,143. This represents a 43.85% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last ninety days, insiders sold 54,453 shares of company stock valued at $5,906,174. 7.40% of the stock is owned by insiders.

Hedge Funds Weigh In On LeMaitre Vascular

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the business. M&T Bank Corp lifted its holdings in shares of LeMaitre Vascular by 2,240.5% in the fourth quarter. M&T Bank Corp now owns 398,069 shares of the medical instruments supplier’s stock valued at $32,283,000 after purchasing an additional 381,061 shares in the last quarter. Goldman Sachs Group Inc. increased its stake in shares of LeMaitre Vascular by 144.4% during the 4th quarter. Goldman Sachs Group Inc. now owns 391,254 shares of the medical instruments supplier’s stock worth $31,731,000 after purchasing an additional 231,157 shares in the last quarter. Bessemer Group Inc. raised its position in shares of LeMaitre Vascular by 292.3% during the 1st quarter. Bessemer Group Inc. now owns 171,838 shares of the medical instruments supplier’s stock worth $18,759,000 after purchasing an additional 128,033 shares during the last quarter. Millennium Management LLC raised its position in shares of LeMaitre Vascular by 119.8% during the 1st quarter. Millennium Management LLC now owns 211,222 shares of the medical instruments supplier’s stock worth $17,722,000 after purchasing an additional 115,141 shares during the last quarter. Finally, First Trust Advisors LP lifted its stake in LeMaitre Vascular by 13.4% in the 4th quarter. First Trust Advisors LP now owns 940,140 shares of the medical instruments supplier’s stock valued at $76,245,000 after buying an additional 111,193 shares in the last quarter. Institutional investors and hedge funds own 84.64% of the company’s stock.

LeMaitre Vascular Trading Down 18.0%

The business has a 50 day moving average of $97.41 and a 200-day moving average of $100.04. The stock has a market cap of $1.98 billion, a PE ratio of 32.00, a price-to-earnings-growth ratio of 2.88 and a beta of 0.53. The company has a current ratio of 14.32, a quick ratio of 12.20 and a debt-to-equity ratio of 0.42.

LeMaitre Vascular Company Profile

LeMaitre Vascular, Inc is a specialty medical device company focused on the development, manufacture and marketing of products for the treatment of peripheral vascular disease. Headquartered in Burlington, Massachusetts, the company’s offerings include a broad portfolio of vascular surgical instruments, grafts, patches, catheters and embolic protection devices. LeMaitre’s product lines address key areas such as arterial reconstruction, endovascular repair and vascular access, serving the needs of cardiovascular surgeons and interventional specialists.

Founded in 1983 by George D.